TMPH inhibitor | CAS#849461-90-1| MedKoo

MedKoo Cat#: 556131 | Name: TMPH inhibitor

Description:

WARNING: This product is for research use only, not for human or veterinary use.

TMPH is an inhibitor of CNS nicotinic receptor. Evaluation of nicotinic acetylcholine receptor (nAChR) subunits expressed in Xenopus laevis oocytes indicated that TMPH can produce a potent and long-lasting inhibition of neuronal nAChR formed by the pairwise combination of the most abundant neuronal α (i.e., α3 and α4) and β subunits (β2 and β4), with relatively little effect, because of rapid reversibility of inhibition, on muscle-type (α1β1γδ) or α7 receptors.

Chemical Structure

TMPH inhibitor

CAS#849461-90-1

Theoretical Analysis

MedKoo Cat#: 556131

Name: TMPH inhibitor

CAS#: 849461-90-1

Chemical Formula: C16H31NO2

Exact Mass: 269.2355

Molecular Weight: 269.43

Elemental Analysis: C, 71.33; H, 11.60; N, 5.20; O, 11.88

Price and Availability

Size	Price	Availability
100mg	USD 750.00	2 Weeks
200mg	USD 1,250.00	2 Weeks
500mg	USD 2,650.00	2 Weeks
1g	USD 3,850.00	2 Weeks
2g	USD 6,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

TMPH; TMPH inhibitor; nAChR-IN-1; nAChR IN-1; nAChR-IN 1

IUPAC/Chemical Name

2,2,6,6-Tetramethyl-4-piperidinyl heptanoate

InChi Key

PWWKJRFUJIFGGD-UHFFFAOYSA-N

InChi Code

InChI=1S/C16H31NO2/c1-6-7-8-9-10-14(18)19-13-11-15(2,3)17-16(4,5)12-13/h13,17H,6-12H2,1-5H3

SMILES Code

CCCCCCC(OC1CC(C)(C)NC(C)(C)C1)=O

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 269.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Yun H, You JE, Hong JK, Kim DY, Lee JU, Kang DH, Ryu YS, Koh DI, Jin DH. TCOF1 promotes the colorectal cancer progression by stabilizing β-catenin. Med Oncol. 2023 Nov 7;40(12):348. doi: 10.1007/s12032-023-02218-z. PMID: 37935810. 2: Asano Y, Matsumoto Y, He F, Katsuyama T, Katsuyama E, Tsuji S, Kamioka H, La Rose J, Rottapel R, Wada J. Pharmacologic inhibition of PARP5, but not that of PARP1 or 2, promotes cytokine production and osteoclastogenesis through different pathways. Clin Exp Rheumatol. 2023 Sep;41(9):1735-1745. doi: 10.55563/clinexprheumatol/qf55h8. Epub 2023 Jan 23. PMID: 36700637. 3: Huang J, Qu Q, Guo Y, Xiang Y, Feng D. Tankyrases/β-catenin Signaling Pathway as an Anti-proliferation and Anti-metastatic Target in Hepatocarcinoma Cell Lines. J Cancer. 2020 Jan 1;11(2):432-440. doi: 10.7150/jca.30976. PMID: 31897238; PMCID: PMC6930431. 4: Katoh M. Multi‑layered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/β‑catenin signaling activation (Review). Int J Mol Med. 2018 Aug;42(2):713-725. doi: 10.3892/ijmm.2018.3689. Epub 2018 May 17. PMID: 29786110; PMCID: PMC6034925. 5: Katoh M. Canonical and non-canonical WNT signaling in cancer stem cells and their niches: Cellular heterogeneity, omics reprogramming, targeted therapy and tumor plasticity (Review). Int J Oncol. 2017 Nov;51(5):1357-1369. doi: 10.3892/ijo.2017.4129. Epub 2017 Sep 19. PMID: 29048660; PMCID: PMC5642388. 6: Arqués O, Chicote I, Puig I, Tenbaum SP, Argilés G, Dienstmann R, Fernández N, Caratù G, Matito J, Silberschmidt D, Rodon J, Landolfi S, Prat A, Espín E, Charco R, Nuciforo P, Vivancos A, Shao W, Tabernero J, Palmer HG. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer. Clin Cancer Res. 2016 Feb 1;22(3):644-56. doi: 10.1158/1078-0432.CCR-14-3081. Epub 2015 Jul 29. PMID: 26224873. 7: Shultz MD, Cheung AK, Kirby CA, Firestone B, Fan J, Chen CH, Chen Z, Chin DN, Dipietro L, Fazal A, Feng Y, Fortin PD, Gould T, Lagu B, Lei H, Lenoir F, Majumdar D, Ochala E, Palermo MG, Pham L, Pu M, Smith T, Stams T, Tomlinson RC, Touré BB, Visser M, Wang RM, Waters NJ, Shao W. Identification of NVP-TNKS656: the use of structure-efficiency relationships to generate a highly potent, selective, and orally active tankyrase inhibitor. J Med Chem. 2013 Aug 22;56(16):6495-511. doi: 10.1021/jm400807n. Epub 2013 Aug 13. PMID: 23844574.